Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Breast cancer, Kisqali
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
FDA Expands Approval of Ribociclib to Early Breast Cancer
The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breast cancer. Already approved in the metastatic setting, the CDK4/6 inhibitor is now also indicated for patients with stages II-III disease who have hormone receptor (HR)-positive/HER2-negative tumors and a high risk for recurrence following surgery.
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
FDA expands use of breast cancer drug Kisqali
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.
Novartis’ Kisqali combination granted FDA approval for early breast cancer patients
Novartis’ Kisqali (ribociclib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for early breast cancer. The CDK4/6 inhibitor has been authorised in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative stage 2 and 3 early breast cancer that is at high risk of recurrence,
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
FDA Expands Approval Of Breast Cancer Drug Kisqali To Earlier-stage Patients
Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
The American Journal of Managed Care
6d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved
ribociclib
(Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early
breast
cancer
. The FDA approved
ribociclib
(Kisqali) with an aromatase ...
Targeted Oncology
5d
Ribociclib-Based Therapy Extends Survival in HR+/HER2– Breast Cancer
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Shooting suspect left note
1951 kidnap victim found
Alabama mass shooting
Tech ban proposed
Daylight saving time
Makes emergency landing
Astronauts return to Earth
Robinson loses key staff
California plastic bag ban
Visits US ammunition plant
Economic speech this week
No govt. shutdown for now
Dolphins legend Morris dies
To meet Vietnamese pres
SpaceX plans Mars missions
San Francisco homelessness
No. 1 at box office again
Free COVID-19 tests
Ga. suspect's mom indicted
Donlon's homes searched
PM Modi visits US
Released after guilty plea
Former WA governor dies
ISR raids Al Jazeera office
Iran coal mine blast
CA firefighter held for arson
CA bill to protect kids online
Feedback